Roche, Genentech, Recursion Launch Up-to-$12B AI Drug Discovery Effort
Roche and its Genentech subsidiary have committed up to $12 billion to Recursion in return for using its Recursion Operating System (OS) to advance therapies in 40 programs that include “key areas” of neuroscience and an undisclosed oncology indication.
Source: genengnews.com